Suppr超能文献

[透析人群中乙肝病毒的自然史]

[Natural history of HBV in dialysis population].

作者信息

Fabrizi F, Martin P, Lunghi G, Ponticelli C

机构信息

Divisione di Nefrologia e Dialisi, Istituto di Igiene e Medicina Preventiva, Ospedale Maggiore, IRCCS, Milano, Italy.

出版信息

G Ital Nefrol. 2004 Jan-Feb;21(1):21-8.

Abstract

Dialysis patients remain at risk of acquiring hepatitis B virus (HBV) infection. The issue of the natural history of HBV among patients undergoing long-term dialysis remains unclear. Assessing the natural history of hepatitis B in patients on maintenance dialysis is problematic because of the unique characteristics of this population: serum aminotransferase activity is lower in dialysis patients compared with patients without renal disease; also, chronic hepatitis B has an insidious and prolonged natural history, and the competing mortality from complications of end-stage renal disease may obscure the long-term consequences of hepatitis B. HBV-related liver disease frequently runs an asymptomatic course in dialysis patients and the liver-related mortality in this population is very low; thus, the prognosis for chronic HBV infection in dialysis patients has been reported as benign. However, the frequency of liver cancer in dialysis patients appears higher than that observed in the general population, this has been related to a greater exposure to HBV/HCV. Cirrhosis is not a frequent comorbid condition in the dialysis population of industrialised countries, but the death rate for dialysis patients with cirrhosis is 35% higher than for those without it. In addition, it has been observed that liver disease remains a significant cause of mortality among HbsAg-positive carriers on dialysis in developing countries. The low viral load measured in dialysis patients with persistent HBsAg carriage could be accounted for by the relatively benign course of HBV-related liver disease in this population. Prospective clinical trials are under way to better define the virological features of HBV in the dialysis population.

摘要

透析患者仍有感染乙型肝炎病毒(HBV)的风险。长期透析患者中HBV的自然史问题仍不明确。评估维持性透析患者的乙型肝炎自然史存在困难,因为该人群具有独特特征:与无肾脏疾病的患者相比,透析患者的血清转氨酶活性较低;此外,慢性乙型肝炎具有隐匿且病程漫长的特点,终末期肾病并发症导致的竞争性死亡可能会掩盖乙型肝炎的长期后果。HBV相关肝病在透析患者中常呈无症状病程,且该人群中与肝脏相关的死亡率很低;因此,据报道透析患者慢性HBV感染的预后良好。然而,透析患者中肝癌的发生率似乎高于普通人群,这与更多接触HBV/HCV有关。在工业化国家的透析人群中,肝硬化并非常见的合并症,但患有肝硬化的透析患者的死亡率比未患肝硬化的患者高35%。此外,据观察,在发展中国家,肝病仍是透析的HBsAg阳性携带者中一个重要的死亡原因。持续性HBsAg携带的透析患者中测得的低病毒载量可能是由于该人群中HBV相关肝病的病程相对良好。目前正在进行前瞻性临床试验,以更好地界定透析人群中HBV的病毒学特征。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验